Sign Out
Polatuzumab vedotin is an antibody-drug conjugate composed of the anti-mitotic agent monomethyl auristatin E (MMAE) covalently conjugated to a CD79b-directed monoclonal antibody (recombinant humanized immunoglobulin G1 [IgG1], produced in Chinese Hamster Ovary cells by recombinant DNA technology).
Polivy 30 mg powder for concentrate for solution for infusion: Each vial of powder for concentrate for solution for infusion contains 30 mg of polatuzumab vedotin.
After reconstitution, each mL contains 20 mg of polatuzumab vedotin.
Polivy 140 mg powder for concentrate for solution for infusion: Each vial of powder for concentrate for solution for infusion contains 140 mg of polatuzumab vedotin.
After reconstitution, each mL contains 20 mg of polatuzumab vedotin.
Excipients/Inactive Ingredients: Succinic acid, Sodium hydroxide (for pH adjustment), Sucrose, Polysorbate 20 (E 432).
